Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Seres Therapeutics (MCRB) Interest & Investment Income (2016 - 2026)

Seres Therapeutics (MCRB) has disclosed Interest & Investment Income for 11 consecutive years, with $445000.0 as the latest value for Q4 2025.

  • Quarterly Interest & Investment Income rose 1.83% to $445000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $2.2 million through Dec 2025, down 43.86% year-over-year, with the annual reading at $2.2 million for FY2025, 43.86% down from the prior year.
  • Interest & Investment Income hit $445000.0 in Q4 2025 for Seres Therapeutics, down from $618000.0 in the prior quarter.
  • In the past five years, Interest & Investment Income ranged from a high of $2.6 million in Q3 2023 to a low of $384000.0 in Q1 2022.
  • Historically, Interest & Investment Income has averaged $971150.0 across 5 years, with a median of $740500.0 in 2021.
  • Biggest five-year swings in Interest & Investment Income: skyrocketed 1020.27% in 2021 and later crashed 77.83% in 2024.
  • Year by year, Interest & Investment Income stood at $485000.0 in 2021, then soared by 191.55% to $1.4 million in 2022, then surged by 39.39% to $2.0 million in 2023, then plummeted by 77.83% to $437000.0 in 2024, then increased by 1.83% to $445000.0 in 2025.
  • Business Quant data shows Interest & Investment Income for MCRB at $445000.0 in Q4 2025, $618000.0 in Q3 2025, and $546000.0 in Q2 2025.